Showing 1 - 3 results of 3 for search 'Mayer N Fishman', query time: 0.02s Refine Results
  1. 1
    A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.

    A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting. by Mayer N Fishman, Jin Tomshine, William J Fulp, Pamela K Foreman

    Published 2015-01-01
    Get full text
    Article
  2. 2
    Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

    Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition by Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott

    Published 2019-02-01
    Get full text
    Article
  3. 3
    Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer

    Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer by Michael Poch, MacLean Hall, Autumn Joerger, Krithika Kodumudi, Matthew Beatty, Pasquale P. Innamarato, Brittany L. Bunch, Mayer N. Fishman, Jingsong Zhang, Wade J. Sexton, Julio M. Pow-Sang, Scott M. Gilbert, Philippe E. Spiess, Jasreman Dhillon, Linda Kelley, John Mullinax, Amod A Sarnaik, Shari Pilon-Thomas

    Published 2018-09-01
    Get full text
    Article

Search Tools: